Este trabalho descreve o desenvolvimento de um biossensor contendo transdução condutométrica sem contato (C4D, capacitively coupled contactless conductivity detection) e ácido fólico (FA) como biorreceptor em microchip, uma nova alternativa que poderá ser utilizada na determinação do biomarcador tumoral FR-α. Essa espécie exibe interações com FA altamente específicas, com constantes de formação da ordem de 109-1010. Os dispositivos microfluídicos, os quais consistiram de uma lâmina de vidro (integrando os eletrodos), dielétrico (contendo a fase biossensora) e substrato de poli(dimetilsiloxano) (PDMS, incorporando os microcanais), foram fabricados utilizando-se processos de fotolitografia e deposição de filmes finos em fase vapor. Objetivando melhorias nos níveis de detecção da C4D, estudos de sensibilidade com base em parâmetros da curva analítica foram conduzidos alterando-se a natureza do dielétrico e a configuração dos eletrodos. Posteriormente, estudos de caracterização foram realizados para as superfícies modificadas com os intermediários de imobilização; condições reacionais distintas (reagente, concentração, solvente e tempo) foram consideradas. As técnicas de microscopia eletrônica de varredura e espectroscopia de fotoelétrons excitados por raios-X foram usadas, respectivamente, a fim de se verificar a possível formação de aglomerados e permitir determinações qualitativas e quantitativas sobre as composições químicas das superfícies. Como resultado dos experimentos de sensibilidade e caracterização de superfície, adotamos os parâmetros seguintes para os ensaios de interações biomoleculares posteriores: filme de SiO2 como dielétrico, eletrodos seletivos à C4D com formato retangular e orientação antiparalela e monocamadas automontadas do reagente 3-aminopropil(trietoxisilano) como intermediário de imobilização de FA. As duas etapas finais do trabalho foram: otimização do tempo de funcionalização com FA (3, 5 e 7 h) e caracterização da fase biossensora, realizada a partir de medidas de C4D e microscopia de força atômica (AFM). Para o primeiro caso, os microchips foram aplicados a um padrão de anticorpo monoclonal específico a FA (α-FA). Os ensaios biomoleculares indicaram uma adsorção efetiva de FA junto à superfície de SiO2 silanizada, sem a ocorrência (ao menos em níveis significativos) de impedimentos estéricos de sua espécie bioativa. Dentre os tempos de funcionalização investigados, 3 h foi aquele que resultou em uma maior sensibilidade do método. Em termos da etapa de caracterização eletroquímica da fase biossensora, seus resultados mostraram haver correlação entre a resposta analítica e as interações FA/α-FA. Em adição, conforme indicaram as medidas de AFM, não houve alterações drásticas na morfologia do substrato (SiO2) em função dos processos de modificação química de superfície. Por fim, o uso da C4D como uma técnica de transdução em biossensores mostrou-se uma alternativa promissora para a análise do biomarcador tumoral FR-α. Dentre outros aspectos, essa plataforma analítica requer uma instrumentação simples, barata e portátil, não apresenta inconvenientes relacionados ao contato eletrodo/solução, dispensa o uso de mediadores redox e permite a determinação simultânea de multianalitos. Neste ínterim, alterações no transdutor devem ser implementadas visando um aumento na sensibilidade do método, o qual representa seu fator limitante principal. / This work describes the development of a biosensor containing capacitively coupled contactless conductivity transduction (C4D) and folic acid (FA) as bioreceptor in microchip, a new alternative that can be used in FR-α tumor biomarker analysis. FR-α exhibits highly specific interactions with FA, showing formation constants of the order of 109-1010. The microfluidic devices consisted of a glass layer (integrating the electrodes), dielectric (containing the biosensor phase), and poly(dimetilsiloxane) substrate (PDMS, incorporating microchannel). The microfabrication stage evolved photolithography processes, metal adsorption via sputtering, and plasma-enhanced vapor film deposition. In order to improve detection levels of C4D, sensitivity studies were conducted by changing the dielectric nature and electrode configuration. Through flow analysis with given electrolyte standards, the limits of detection and quantification were calculated based on analytical curve parameters. Subsequently, researches were performed to characterize the modified surfaces with immobilization intermediate considering reaction conditions distinct (reagent, concentration, solvent, and time). The techniques of scanning electron microscopy and X-ray photoelectron spectroscopy were employed, respectively, aiming to verify the clusters formation and allow qualitative and quantitative determinations about the surfaces chemical composition. From the results of sensitivity experiments and surface characterization, we adopt the following parameters for the biomolecular interactions assays: SiO2 film as dielectric, C4D selective electrodes with rectangular shape and antiparallel orientation, and self-assembled monolayers of 3-aminopropyl(triethoxysilane) as intermediary for immobilization of FA. The two final steps of the work were: optimizing the FA functionalization time (3, 5, and 7 h) and phase biosensor characterization, made from measures of C4D and atomic force microscopy (AFM). For the first case, due to the absence of FR-α standard for purchase, the microchips were applied to FA specific monoclonal antibody (α-FA). The biomolecular assay indicated effective adsorption of FA, without occurrence (at least in significant levels) of steric hindrance of its bioactive specie. Among the investigated times of functionalization, 3 h resulted in a higher sensitivity of the method. In terms of biosensor phase electrochemical characterization stage, their results evidenced correlation between analytical response and FA/α-FA interactions. Additionally, as the AFM measurements showed, drastic changes in the morphology of the substrate (SiO2) with the surface modification processes did not occur. Finally, the use of the C4D as transduction technical in biosensors proved to be a promissory alternative for FR-α tumor biomarker analysis. Among other features, this platform has not drawbacks related to the electrode/solution contact, dispenses the use of redox mediators, allows the simultaneous determination of multianalytes, and employs an instrumentation that is simple, cheap, and portable. Nevertheless, changes in the transducer should be implemented to increase the method sensitivity, which represents its main limiting factor.

Este trabalho descreve o desenvolvimento de um biossensor contendo transdução condutométrica sem contato (C4D, capacitively coupled contactless conductivity detection) e ácido fólico (FA) como biorreceptor em microchip, uma nova alternativa que poderá ser utilizada na determinação do biomarcador tumoral FR-α. Essa espécie exibe interações com FA altamente específicas, com constantes de formação da ordem de 109-1010. Os dispositivos microfluídicos, os quais consistiram de uma lâmina de vidro (integrando os eletrodos), dielétrico (contendo a fase biossensora) e substrato de poli(dimetilsiloxano) (PDMS, incorporando os microcanais), foram fabricados utilizando-se processos de fotolitografia e deposição de filmes finos em fase vapor. Objetivando melhorias nos níveis de detecção da C4D, estudos de sensibilidade com base em parâmetros da curva analítica foram conduzidos alterando-se a natureza do dielétrico e a configuração dos eletrodos. Posteriormente, estudos de caracterização foram realizados para as superfícies modificadas com os intermediários de imobilização; condições reacionais distintas (reagente, concentração, solvente e tempo) foram consideradas. As técnicas de microscopia eletrônica de varredura e espectroscopia de fotoelétrons excitados por raios-X foram usadas, respectivamente, a fim de se verificar a possível formação de aglomerados e permitir determinações qualitativas e quantitativas sobre as composições químicas das superfícies. Como resultado dos experimentos de sensibilidade e caracterização de superfície, adotamos os parâmetros seguintes para os ensaios de interações biomoleculares posteriores: filme de SiO2 como dielétrico, eletrodos seletivos à C4D com formato retangular e orientação antiparalela e monocamadas automontadas do reagente 3-aminopropil(trietoxisilano) como intermediário de imobilização de FA. As duas etapas finais do trabalho foram: otimização do tempo de funcionalização com FA (3, 5 e 7 h) e caracterização da fase biossensora, realizada a partir de medidas de C4D e microscopia de força atômica (AFM). Para o primeiro caso, os microchips foram aplicados a um padrão de anticorpo monoclonal específico a FA (α-FA). Os ensaios biomoleculares indicaram uma adsorção efetiva de FA junto à superfície de SiO2 silanizada, sem a ocorrência (ao menos em níveis significativos) de impedimentos estéricos de sua espécie bioativa. Dentre os tempos de funcionalização investigados, 3 h foi aquele que resultou em uma maior sensibilidade do método. Em termos da etapa de caracterização eletroquímica da fase biossensora, seus resultados mostraram haver correlação entre a resposta analítica e as interações FA/α-FA. Em adição, conforme indicaram as medidas de AFM, não houve alterações drásticas na morfologia do substrato (SiO2) em função dos processos de modificação química de superfície. Por fim, o uso da C4D como uma técnica de transdução em biossensores mostrou-se uma alternativa promissora para a análise do biomarcador tumoral FR-α. Dentre outros aspectos, essa plataforma analítica requer uma instrumentação simples, barata e portátil, não apresenta inconvenientes relacionados ao contato eletrodo/solução, dispensa o uso de mediadores redox e permite a determinação simultânea de multianalitos. Neste ínterim, alterações no transdutor devem ser implementadas visando um aumento na sensibilidade do método, o qual representa seu fator limitante principal. / This work describes the development of a biosensor containing capacitively coupled contactless conductivity transduction (C4D) and folic acid (FA) as bioreceptor in microchip, a new alternative that can be used in FR-α tumor biomarker analysis. FR-α exhibits highly specific interactions with FA, showing formation constants of the order of 109-1010. The microfluidic devices consisted of a glass layer (integrating the electrodes), dielectric (containing the biosensor phase), and poly(dimetilsiloxane) substrate (PDMS, incorporating microchannel). The microfabrication stage evolved photolithography processes, metal adsorption via sputtering, and plasma-enhanced vapor film deposition. In order to improve detection levels of C4D, sensitivity studies were conducted by changing the dielectric nature and electrode configuration. Through flow analysis with given electrolyte standards, the limits of detection and quantification were calculated based on analytical curve parameters. Subsequently, researches were performed to characterize the modified surfaces with immobilization intermediate considering reaction conditions distinct (reagent, concentration, solvent, and time). The techniques of scanning electron microscopy and X-ray photoelectron spectroscopy were employed, respectively, aiming to verify the clusters formation and allow qualitative and quantitative determinations about the surfaces chemical composition. From the results of sensitivity experiments and surface characterization, we adopt the following parameters for the biomolecular interactions assays: SiO2 film as dielectric, C4D selective electrodes with rectangular shape and antiparallel orientation, and self-assembled monolayers of 3-aminopropyl(triethoxysilane) as intermediary for immobilization of FA. The two final steps of the work were: optimizing the FA functionalization time (3, 5, and 7 h) and phase biosensor characterization, made from measures of C4D and atomic force microscopy (AFM). For the first case, due to the absence of FR-α standard for purchase, the microchips were applied to FA specific monoclonal antibody (α-FA). The biomolecular assay indicated effective adsorption of FA, without occurrence (at least in significant levels) of steric hindrance of its bioactive specie. Among the investigated times of functionalization, 3 h resulted in a higher sensitivity of the method. In terms of biosensor phase electrochemical characterization stage, their results evidenced correlation between analytical response and FA/α-FA interactions. Additionally, as the AFM measurements showed, drastic changes in the morphology of the substrate (SiO2) with the surface modification processes did not occur. Finally, the use of the C4D as transduction technical in biosensors proved to be a promissory alternative for FR-α tumor biomarker analysis. Among other features, this platform has not drawbacks related to the electrode/solution contact, dispenses the use of redox mediators, allows the simultaneous determination of multianalytes, and employs an instrumentation that is simple, cheap, and portable. Nevertheless, changes in the transducer should be implemented to increase the method sensitivity, which represents its main limiting factor.

Despite the progress made in cancer research, cancer remains one of the leading causes of death worldwide. Although the development of new cancer treatments has improved cancer patients' survival rate, a significant number of patients experience refractory and recurrence events with serious side effects. It is known that the immune system actively participates in eliminating cancer. However, cancer cells can develop mechanisms to evade the immune system resulting in immunotolerance. Immunotherapy aids the patient's immune system's ability to recognize and eliminate cancer cells. During the last three decades, immunotherapy has gradually emerged as an effective and more specific approach to treat cancer. Particularly monoclonal antibodies and adoptive cell therapies such as chimeric antigen receptor (CAR) T-cells have proven highly effective. Nevertheless, the success of these novel therapies depends on discovering suitable tumor targets. Recently, we reported localization of Thymidine Kinase 1 (TK1) to the plasma membrane of certain cancer cells but have not found such localization on normal cells. Similarly, another nucleotide salvage pathway enzyme Hypoxanthine Guanine Phosphoribosyltransferase (HPRT), has also been reported to be localized to the plasma membrane of certain cancer cells. Thus, TK1 and HPRT membrane-associated forms can be potential tumor targets for cancer immunotherapy. This dissertation describes the immunotargeting of TK1 for the selective elimination of tumor cells and the surface localization of HPRT on the plasma membrane of cancer cells. Using hybridoma and phage display technologies, we developed monoclonal antibodies (mAb) and isolated human single domain antibodies (sdAb) specific to human TK1. We confirmed that antibodies and sdAbs could target TK1 on the plasma membrane of lung, breast and colon cancer cells, but not on healthy cells. In addition, we demonstrated that cancer cells expressing membrane-associated TK1 (mTK1) co-cultured with human mononuclear cells (MNC) were selectively eliminated through antibody-dependent cell-mediated cytotoxicity (ADCC) when anti-TK1 mAbs were added. Furthermore, we designed novel TK1 specific tumor targeting receptors and expressed them in human T cells and human macrophages. Finally, we proposed using both TK1 and HPRT as biomarkers for the early detection and monitoring of follicular lymphoma (FL), a disease that is usually detected at advanced stages. The knowledge generated from the data presented in this dissertation indicates that TK1 and HPRT may be suitable immunotherapeutic targets for antibody-based and adoptive cell-based therapies against both liquid and solid malignancies. It also proposes the incorporation of TK1 and HPRT as molecular biomarkers for the early detection and monitoring of FL.

Chacune de nos cellules possède l’information génétique nécessaire à la constitution de l’organisme entier, mais les cellules différenciées n’expriment qu’un répertoire restreint de gènes. Le contrôle des expressions des gènes apparaît fondamental dans la mise en place et le maintien de l’identité cellulaire. Le contrôle transcriptionnel, premier niveau de régulation de l’expression des gènes, est basé sur l’intégrité de la séquence génique et sur son accessibilité, elle-même conditionnée par les mécanismes épigénétiques contrôlant la dynamique chromatinienne. Dans un contexte pathologique, des altérations génétiques et/ou épigénétiques pourront alors être à l’origine de dérégulations géniques et mener à des fonctions cellulaires altérées. Lors du développement d’un carcinome bronchique, les cellules pulmonaires acquièrent une capacité de prolifération incontrôlée et une résistance accrue à l’apoptose. Ces caractéristiques phénotypiques, bases de la croissance tumorale, sont le reflet des anomalies qui s’accumulent dans le génome des cellules cancéreuses. Aux altérations génétiques somatiques (mutations ponctuelles, remaniements chromosomiques) s’ajoute un bouleversement global du paysage épigénétique, le tout conduisant une crise de l’identité cellulaire et à des dérégulations massives des expressions géniques. Alors que la répression aberrante de gènes (notamment des gènes suppresseurs de tumeur) a été largement étudiée, l’activation ectopique de gènes normalement silencieux demeure un aspect plus méconnu. Notre hypothèse de travail est que les expressions hors-contexte de gènes tissu-spécifiques puissent être non seulement impliquées dans le phénomène de cancérogenèse, mais également constituer des biomarqueurs tumoraux ou cibles thérapeutiques innovantes. Dans cette thèse, notre attention s’est portée sur le gène PRL codant la prolactine, normalement exprimée dans l’hypophyse et absente du poumon non tumoral. Nous avons détecté une activation ectopique du gène PRL dans 10% des tumeurs pulmonaires, principalement des tumeurs neuroendocrines. Nous avons observé que l’expression de PRL est associée à des tumeurs particulièrement agressives et à un pronostic sombre pour les patients. Nous avons également démontré que l’expression de PRL confère aux cellules cancéreuses pulmonaires une résistance accrue à un stress génotoxique. De manière inattendue, nos résultats suggèrent que l’effet oncogène de l’expression de PRL ne repose pas sur les mécanismes d’action classique de la prolactine et nous avons dû remettre en question l’hypothèse initiale d’une sécrétion de l’hormone par les cellules cancéreuses pulmonaires et d’une action autocrine/paracrine au sein de la tumeur via l’activation du récepteur à la prolactine. Le récepteur est en effet absent des cellules cancéreuses pulmonaires et le transcrit PRL exprimé est dépourvu de ses premiers exons, ce qui pourrait conduire à la production d’une protéine tronquée de son peptide signal, incapable d’emprunter la voie de sécrétion classique, et par conséquent retenue à l’intérieur de la cellule cancéreuse pulmonaire. Même si les mécanismes d’action in cellulo de la prolactine restent à décrypter, nos données suggèrent que l’expression ectopique de PRL pourrait constituer une nouvelle cible thérapeutique dans le traitement des tumeurs pulmonaires agressives. Ce travail de thèse, incluant également des résultats complémentaires obtenus sur trois gènes spécifiques du testicule exprimés de manière aberrante dans les tumeurs pulmonaires (BRDT, SOX30 et SPATA22) met en lumière l’intérêt des expressions ectopiques. Celles-ci peuvent en effet fournir de nouveaux outils de diagnostic et de pronostic aux cliniciens, mais également de nouvelles approches ciblées en complément des thérapies classiques qui ne suffisent pas à limiter la mortalité importante due aux néoplasies pulmonaires. / Each human cell contains a genome carrying all the genetic information necessary for the constitution of the whole organism. However, differentiated cells express only a restricted repertoire of genes. The control of gene expressions is fundamental for the establishment and maintenance of cell identity. The first level of gene expression regulation, the transcriptional control, is based on the integrity of the gene sequence but also on its accessibility, itself dependent on a set of epigenetic mechanisms that control chromatin dynamics. In a pathological context, genetic and epigenetic alterations can lead to gene deregulations and altered cellular functions. During the bronchial carcinogenesis, lung cancer cells acquire a capacity of uncontrolled proliferation and an increased resistance to cell death. These phenotypic characteristics, favoring tumor growth, result from abnormalities that accumulate in the genome of cancer cells. These are somatic genetic alterations, from point mutations to large-scale chromosomal rearrangements, but also a global disruption of the epigenetic landscape – both leading to an identity crisis and to gene deregulations. While the phenomenon of aberrant gene repression (including repression of tumor suppressor genes) has been extensively studied, ectopic activation of normally silent genes remains poorly understood. Our hypothesis is that the “out of context” expression of tissue-specific genes not only could be involved in carcinogenesis, but could also be of high interest as tumor biomarkers or novel therapeutic targets. In this work, we focused on the prolactin-encoding PRL gene, normally mainly expressed in the pituitary gland and absent from non-tumor lung. We detected an ectopic PRL gene activation in 10% of lung tumors, mainly neuroendocrine tumors. We observed that PRL expression is associated with aggressive tumors and a poor prognosis for patients. We also found that the expression of PRL is associated with an increased resistance of lung cancer cells to a genotoxic stress. Unexpectedly, our data suggest that the oncogenic action of PRL expression is not based on the conventional mechanisms of prolactin action, and we did not confirm the initial hypothesis of a secretion by lung cancer cells of the prolactin hormone, and its action in an autocrine/paracrine loop within the tumor through the activation of the prolactin receptor. Indeed, the receptor is absent in lung cancer cells and the transcribed PRL mRNA is missing its first exons, possibly leading to the production of a truncated prolactin protein, without a functional signal peptide, therefore unable to follow the classical secretion pathway and retained inside the cancer cell. Although the detailed mechanisms of prolactin action in lung cancer remain to be deciphered, our study suggests that the ectopic expression of PRL could be used as a new therapeutic target in the treatment of aggressive lung tumors. This work, also including additional results on three testis-specific genes aberrantly expressed in lung tumors (BRDT, SOX30 and SPATA22) highlights the interest of studying ectopic gene expressions in tumor cells, which can provide new diagnosis and prognosis tools for clinicians as well as new targeted approaches that could be used in addition to conventional lung cancer therapies, which are presently insufficient to limit the high mortality due to lung neoplasms.